Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (221-230 of 293) with videos related to

Pageof 30
Sort By:
BMC Musculoskeletal Disorders|January 14, 2014
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme diseaseNicolas W J Schröder, Isabel Diterich, Antje Zinke, et al.
Arthritis Research & Therapy|March 24, 2018
Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosisFlorian Weigold, Jeannine Günther, Moritz Pfeiffenberger, et al.
Drug Safety|February 2, 2020
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataGerd R Burmester, Jeffrey R Curtis, Huifeng Yun, et al.
Rheumatology and Therapy|January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 YearsChristina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.
RMD Open|October 10, 2022
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccinationElisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau, et al.
Expert Opinion on Biological Therapy|June 21, 2024
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I studyKyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, et al.
Pageof 30

Showing results (221-230 of 293) with videos related to

Sort By:
Pageof 30
BMC Musculoskeletal Disorders|January 14, 2014
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION studyHubert G Nüßlein, Rieke Alten, Mauro Galeazzi, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 6, 2005
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme diseaseNicolas W J Schröder, Isabel Diterich, Antje Zinke, et al.
Arthritis Research & Therapy|March 24, 2018
Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosisFlorian Weigold, Jeannine Günther, Moritz Pfeiffenberger, et al.
Drug Safety|February 2, 2020
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational DataGerd R Burmester, Jeffrey R Curtis, Huifeng Yun, et al.
Rheumatology and Therapy|January 5, 2024
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 YearsChristina Charles-Schoeman, Jon T Giles, Nancy E Lane, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.
RMD Open|October 10, 2022
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccinationElisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau, et al.
Expert Opinion on Biological Therapy|June 21, 2024
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I studyKyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, et al.
Pageof 30